Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial.
Patel PM, Ottensmeier CH, Mulatero C, Lorigan P, Plummer R, Pandha H, Elsheikh S, Hadjimichael E, Villasanti N, Adams SE, Cunnell M, Metheringham RL, Brentville VA, Machado L, Daniels I, Gijon M, Hannaman D, Durrant LG.
Patel PM, et al. Among authors: brentville va.
Oncoimmunology. 2018 Feb 22;7(6):e1433516. doi: 10.1080/2162402X.2018.1433516. eCollection 2018.
Oncoimmunology. 2018.
PMID: 29872563
Free PMC article.